HC Wainwright upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research note published on Thursday, Zacks.com reports.
Bradmer Pharmaceuticals Price Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported C($0.55) earnings per share (EPS) for the quarter.
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Choose Top Rated Stocks
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.